ReviewFrontiers in nutrition2022
Gut Dysbiosis in Pancreatic Diseases: A Causative Factor and a Novel Therapeutic Target.
Review in Frontiers in nutrition, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Use of probiotics and similar in pediatric patients with Type 1 Diabetes Mellitus: a systematic review.Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo · 2024Pooled it
- The gut-pancreas axis: microbial dysbiosis as a pathogenic driver of diabetes and pancreatic cancer.Medical oncology (Northwood, London, England) · 2026Review
- Beyond the Pancreas: The Gut Microbiota in Acute Pancreatitis - From Mechanisms to Therapeutic Perspectives.Clinical and experimental gastroenterology · 2026Review
- Exploring the role of the gut microbiome in pediatric gastrointestinal and neurological health.Translational pediatrics · 2025Review
- Implications of gut microbiota in hepatic and pancreatic diseases: Gut-liver-pancreas axis.World journal of hepatology · 2025Article
- The early-life gut microbiome in common pediatric diseases: roles and therapeutic implications.Frontiers in nutrition · 2025Review
- Gut microbiota-based biomarkers for precision subtype classification and mechanistic understanding of biliary and hyperlipidemic acute pancreatitis.Frontiers in microbiology · 2025Article
- The Importance of Microbiota and Fecal Microbiota Transplantation in Pancreatic Disorders.Diagnostics (Basel, Switzerland) · 2024Review
- Exploring the Microbial Landscape: Gut Dysbiosis and Therapeutic Strategies in Pancreatitis-A Narrative Review.Biomedicines · 2024Review
- Microbiome as a biomarker and therapeutic target in pancreatic cancer.BMC microbiology · 2024Review
- Article
- The close association of Muribaculum and PA (10:0/a-17:0) with the occurrence of pancreatic ductal adenocarcinoma and immunotherapy.Frontiers in immunology · 2024Article
- A Blood-based Metabolite Signature for Personalized Risk Assessment of Pancreatic Cancer.Journal of cancer immunology · 2024Article
- HGF/c-Met pathway inhibition combined with chemotherapy increases cytotoxic T-cell infiltration and inhibits pancreatic tumour growth and metastasis.Cancer letters · 2023Article
- Therapeutic Approaches in Pancreatic Cancer: Recent Updates.Biomedicines · 2023Review
- A Concerted Vision to Advance the Knowledge of Diabetes Mellitus Related to Immune Checkpoint Inhibitors.International journal of molecular sciences · 2023Review
- Review
- Probiotics enhances anti-tumor immune response induced by gemcitabine plus cisplatin chemotherapy for urothelial cancer.Cancer science · 2023Article
- Gut microbiota interacts with inflammatory responses in acute pancreatitis.Therapeutic advances in gastroenterology · 2023Review
- Causal link between gut microbiota and four types of pancreatitis: a genetic association and bidirectional Mendelian randomization study.Frontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic-related disorders such as pancreatitis, pancreatic cancer, and type 1 diabetes mellitus (T1DM) impose a substantial challenge to human health and wellbeing. Even though our understanding of the initiation and progression of pancreatic diseases has broadened over time, no effective therapeutics is yet available for these disorders. Mounting evidence suggests that gut dysbiosis is closely related to human health and disease, and pancreatic diseases are no exception. Now much effort is under way to explore the correlation and eventually potential causation between the gut microbiome and the course of pancreatic diseases, as well as to develop novel preventive and/or therapeutic strategies of targeted microbiome modulation by probiotics, prebiotics, synbiotics, postbiotics, and fecal microbiota transplantation (FMT) for these multifactorial disorders. Attempts to dissect the intestinal microbial landscape and its metabolic profile might enable deep insight into a holistic picture of these complex conditions. This article aims to review the subtle yet intimate nexus loop between the gut microbiome and pancreatic diseases, with a particular focus on current evidence supporting the feasibility of preventing and controlling pancreatic diseases
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.